New Phase 3 Clinical Study Finds Nutritional Protocol Including Nicotinamide Riboside Accelerates Recovery in Mild-to-Moderate COVID-19 Patients
ChromaDex Corp. (NASDAQ: CDXC) has published Phase 3 study results demonstrating that a nutritional protocol can reduce recovery time in mild-to-moderate COVID-19 patients by 3.5 days. Conducted at Umraniye Teaching and Research Hospital in Turkey, this double-blind trial included 309 participants and assessed the effectiveness of nicotinamide riboside (NR) and other active ingredients. The findings also indicated improved liver health and reduced inflammatory markers, supporting the potential of these metabolic activators in enhancing recovery.
- 3.5-day reduction in recovery time for mild-to-moderate COVID-19 patients.
- Improvement in liver health and decreased inflammatory markers.
- Successful Phase 3 study conducted with 309 outpatients.
- None.
ChromaDex Corp. (NASDAQ: CDXC) today announced results from the study “Combined Metabolic Activators Accelerates Recovery in Mild-to-Moderate COVID-19” were published Feb. 20 on medRxiv, a preprint publication website. The Phase 3 study demonstrated that patients with mild-to-moderate COVID-19 receiving standard of care experienced a 3.5 day reduction in recovery time when receiving an added nutritional protocol. Aimed at improving mitochondrial function, the protocol included nicotinamide riboside (NR), L-serine, N-acetyl-L-cysteine (NAC), and L-carnitine tartrate.
The results of the study, which took place in conjunction with the ChromaDex External Research Program (CERP) and ScandiBio Therapeutics, build on findings from Phase 2 clinical data published in October 2020. The addition of the nutritional protocol, or combined metabolic activators (CMA), to the Turkish standard of care not only reduced recovery time but improved liver health and decreased levels of inflammatory markers.
The randomized, placebo-controlled, and double-blind Phase 3 clinical trial studied 309 outpatients at Umraniye Teaching and Research Hospital, University of Health Sciences, Istanbul, Turkey. Patients were randomly assigned on a 3:1 basis to receive the nutritional protocol or placebo in combination with the Turkish standard of care hydroxychloroquine (HCQ) or favipiravir (FP). Patients received standard of care for 5 days and the nutritional protocol or placebo for 14 days. Clinical status was evaluated through daily telephone visits, and each dose of the nutritional protocol contained 1g NR, 3.73g L-carnitine tartrate, 2.55g NAC, and 12.35g serine, taken twice a day.
“Our Phase 3 data shows that the nutritional protocol significantly improves the recovery, liver health, and markers of inflammation of patients with COVID-19,” says lead investigator Dr. Adil Mardinoglu, professor at KTH—Royal Institute of Technology in Sweden & King’s College London. “Dysfunctional mitochondria have been implicated in worsened progression for COVID-19, and this nutritional intervention helps to remedy the stress put on the body of an infected patient.”
About ChromaDex:
ChromaDex Corp. is a global bioscience company dedicated to healthy aging. The ChromaDex team, which includes world-renowned scientists, is pioneering research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. ChromaDex is the innovator behind NAD+ precursor nicotinamide riboside (NR), which is protected by ChromaDex’s patent portfolio along with other NAD+ precursors. ChromaDex maintains a website at www.chromadex.com to which ChromaDex regularly posts copies of its press releases as well as additional and financial information about the Company.
Forward-Looking Statements:
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, including statements related to the results of clinical studies and whether NR may reduce the recovery time of patients with mild-to-moderate COVID-19. Statements that are not a description of historical facts constitute forward-looking statements and may often, but not always, be identified by the use of such words as "expects," "anticipates," "intends," "estimates," "plans," "potential," "possible," "probable," "believes," "seeks," "may," "will," "should," "could" or the negative of such terms or other similar expressions. More detailed information about ChromaDex and the risk factors that may affect the realization of forward-looking statements is set forth in ChromaDex's Annual Report on Form 10-K for the fiscal year ended December 31, 2019 as amended, ChromaDex's Quarterly Reports on Form 10-Q and other filings submitted by ChromaDex to the SEC, copies of which may be obtained from the SEC's website at www.sec.gov. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and actual results may differ materially from those suggested by these forward-looking statements. All forward-looking statements are qualified in their entirety by this cautionary statement and ChromaDex undertakes no obligation to revise or update this release to reflect events or circumstances after the date hereof.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210224005087/en/
FAQ
What were the results of the Phase 3 study conducted by ChromaDex on COVID-19?
What is the nutritional protocol used in the ChromaDex study for COVID-19?
Where was the ChromaDex Phase 3 COVID-19 study conducted?
How many patients were involved in ChromaDex's COVID-19 study?
What impact could ChromaDex's study results have on the market?
